Eric Sy

Dr. Eric Sy

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Journal of Critical Care
Verified
Journal Article
Closed access
ESEric Sy
Eric Sy
MSMichael C. Sklar
Michael C. Sklar
LLLaurence Lequier
Laurence Lequier
EFEddy Fan
Eddy Fan
HKHussein D. Kanji
Hussein D. Kanji

1 December 2016 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
MSMichael C. Sklar
Michael C. Sklar
ESEric Sy
Eric Sy
LLLaurance Lequier
Laurance Lequier
EFEddy Fan
Eddy Fan
HKHussein D. Kanji
Hussein D. Kanji
Background: The optimal anticoagulation strategy for venovenous extracorporeal membrane oxygenation (VV-ECMO) is not known. Objectives: To evaluate the safety of anticoagulation strategies and monitoring during VV-ECMO for respiratory failure. Data sources: We conducted a systematic review to evaluate the association between anticoagulation strategies during VV-ECMO and prespecified outcomes, including major bleeding episodes, thrombotic events, and in-hospital mortality. We included articles published between 1977 and January 30, 2015. Study quality was assessed using the Newcastle-Ottawa scoring system. A separate meta-analysis was not planned. Data extraction: Data were independently extracted by two authors and collected on a standardized report form. Synthesis: A total of 18 studies (n = 646) were included; 17 studies enrolled patients with acute respiratory distress syndrome. Across all studies, the duration of VV-ECMO support ranged from 4 to 20 days. Patients received an average of 2.3 (±3.9) units of transfused red blood cells per day. The bleeding rate across all studies was 16%, and the rate of thrombosis was 53%. Among seven studies (199 patients) targeting a specified activated partial thromboplastin time (aPTT), there were 37 (19%) major bleeding episodes and 53 (27%) major thromboses. Among five studies (43 patients) with aPTT targets of 60 seconds or greater, there were 24 (56%) bleeding episodes and 3 (7%) clotting events. Three studies (156 patients) with an aPTT target under 60 seconds reported 13 (8%) and 50 (32%) significant bleeding and thrombotic events, respectively. The most commonly reported thrombotic events were circuit-related clotting and deep-vein thrombosis. Mortality during VV-ECMO varied across the studies, ranging from 0 to at least 50% at heterogeneous time points. The total number of deaths for all studies combined was 186 (29%). Conclusions: The role and optimal therapeutic targets for anticoagulation during VV-ECMO are unclear. Previously published studies are limited by retrospective, observational design, small cohorts, and patient heterogeneity. The clinical significance of reported thrombotic complications is largely unknown. This systematic review underscores the need for randomized controlled trials of anticoagulation strategies for patients undergoing VV-ECMO for respiratory failure.

1 February 2019 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
MFMichael Fralick
Michael Fralick
ESEric Sy
Eric Sy
AHAdiba Hassan
Adiba Hassan
MBMatthew J. Burke
Matthew J. Burke
EMElizabeth Mostofsky
Elizabeth Mostofsky
TKTodd Karsies
Todd Karsies
Concussion is defined as a transient disturbance of neurologic function caused by acute trauma.1 Concussion is the most common form of traumatic brain injury (TBI), with approximately 4 million concussions occurring each year in the United States.1 It is increasingly recognized as an injury affecting military personnel.2,3 For approximately 80% of affected individuals, neurologic symptoms resolve within 7 days of injury.1 However, up to 25% of patients experience chronic neuropsychiatric symptoms, including anxiety and depression, that may last years after the initial injury.4

1 November 2018 in Critical Care Medicine
Verified
Journal Article
Closed access
CKConstantine J. Karvellas
Constantine J. Karvellas
EGElisabet Garcia-Lopez
Elisabet Garcia-Lopez
JFJavier Fernandez
Javier Fernandez
FSFaouzi Saliba
Faouzi Saliba
ESEric Sy
Eric Sy
VAVicente Arroyo
Vicente Arroyo
Objectives: To evaluate the Chronic Liver Failure-Consortium Acute on Chronic Liver Failure score in acute on chronic liver failure patients admitted to ICUs from different global regions and compare discrimination ability with previously published scores. Design: Retrospective pooled analysis. Setting: Academic ICUs in Canada (Edmonton, Vancouver) and Europe (Paris, Barcelona, Chronic liver failure/Acute-on-Chronic Liver Failure in Cirrhosis [CANONIC] study). Patients: Sample of analysis of 867 cirrhotic patients with acute on chronic liver failure admitted to ICU. Cumulative incidence functions of death were estimated by acute on chronic liver failure grade at admission and at day 3. Survival discrimination abilities of Chronic Liver Failure-Consortium Acute on Chronic Liver Failure, Model for End-Stage Liver Disease, Acute Physiology and Chronic Health Evaluation II, and Child-Turcotte-Pugh scores were compared. Interventions: ICU admission for organ support. Measurements and Main Results: At admission 169 subjects (19%) had acute on chronic liver failure 1, 302 (35%) acute on chronic liver failure 2, and 396 (46%) had acute on chronic liver failure 3 with 90-mortality rates of 33%, 40%, and 74%, respectively (p < 0.001). At admission, Chronic Liver Failure-Consortium Acute on Chronic Liver Failure demonstrated superior discrimination at 90 days compared with Acute Physiology and Chronic Health Evaluation II (n = 532; concordance index 0.67 vs 0.62; p = 0.0027) and Child-Turcotte-Pugh (n = 666; 0.68 vs 0.64; p = 0.0035), but not Model for End-Stage Liver Disease (n = 845; 0.68 vs 0.67; p = 0.3). A Chronic Liver Failure-Consortium Acute on Chronic Liver Failure score greater than 70 at admission or on day 3 was associated with 90-day mortality rates of approximately 90%. Ninety-day mortality in grade 3 acute on chronic liver failure patients at admission who demonstrated improvement by day 3 was 40% (vs 79% in patients who did not). Conclusions: The Chronic Liver Failure-Consortium Acute on Chronic Liver Failure demonstrated better discrimination at day 28 and day 90 compared with Acute Physiology and Chronic Health Evaluation II and Child-Turcotte-Pugh. Patients who demonstrated clinical improvement post-ICU admission (e.g., acute on chronic liver failure 3 to 1 or 2) at day 3 had better outcomes than those who did not. In high-risk ICU patients (Chronic Liver Failure-Consortium Acute on Chronic Liver Failure > 70), decisions regarding transition to palliation should be explored between patient families and the ICU providers after a short trial of therapy.

1 March 2019 in Liver International
Verified
Journal Article
Closed access
PDF file
FCFilipe Sousa Cardoso
Filipe Sousa Cardoso
JAJuan G. Abraldes
Juan G. Abraldes
ESEric Sy
Eric Sy
JRJuan J. Ronco
Juan J. Ronco
LBLuís Bagulho
Luís Bagulho
CKConstantine J. Karvellas
Constantine J. Karvellas

1 December 2016 in Journal of Critical Care
Verified
Journal Article
Closed access
ESEric Sy
Eric Sy
JRJuan J. Ronco
Juan J. Ronco
RSRowan Searle
Rowan Searle
CKConstantine J. Karvellas
Constantine J. Karvellas